Advertisement

Contemporary Epidemiology of Cirrhosis

  • Jad A. Baki
  • Elliot B. TapperEmail author
Liver (J Bajaj, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Liver

Abstract

Purpose of Review

We sought to review the contemporary epidemiology of cirrhosis, focusing on the relative burden of the most common chronic liver diseases.

Recent Findings

The key findings in the review highlight the increasing prevalence and impact of alcohol-related liver disease, particularly among young people, and the epidemic of nonalcoholic fatty liver commensurate with rising rates of obesity. We also contrast recent advances in the care of persons with hepatitis C with the lamentable rise in new infections associated with intravenous drug use. Finally, we highlight the impact of both conventional complications of cirrhosis (namely hepatic encephalopathy) but also the host of patient-reported outcomes adversely impacted by the symptoms of cirrhosis.

Summary

Cirrhosis is associated with an expanding footprint in contemporary public health. In order to improve global outcomes, we must not only focus on the identifying and treating persons with viral hepatitis but also preventing the rise of alcohol-related liver disease and nonalcoholic fatty liver disease while attending to the urgent patient-centered needs posed by the symptoms of cirrhosis.

Keywords

Liver disease Nonalcoholic fatty liver disease hepatitis C Alcohol 

Notes

Compliance with Ethical Standards

Conflict of Interest

Jad Baki reports no potential conflicts of interest.

Elliot Tapper reports grants from Valeant and Gilead and personal fees from Novartis and Salix.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64(5):1577–86.CrossRefGoogle Scholar
  2. 2.
    Tapper E, Kanwal F, Asrani S, et al. Patient reported outcomes in cirrhosis: a scoping review of the literature. Hepatology (Baltimore, Md). 2017.Google Scholar
  3. 3.
    Gomez EV, Rodriguez YS, Bertot LC, Gonzalez AT, Perez YM, Soler EA, et al. The natural history of compensated HCV-related cirrhosis: a prospective long-term study. J Hepatol. 2013;58(3):434–44.CrossRefGoogle Scholar
  4. 4.
    D'amico G, Pasta L, Morabito A, et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther. 2014;39(10):1180–93.CrossRefGoogle Scholar
  5. 5.
    D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217–31.CrossRefGoogle Scholar
  6. 6.
    Ginés P, Quintero E, Arroyo V, et al. Compensated cirrhosis: Natural history and prognostic factors. Hepatology. 1987;7(1):122–8.CrossRefGoogle Scholar
  7. 7.
    •• Mellinger JL, Shedden K, Winder GS, et al. The high burden of alcoholic cirrhosis in privately insured persons in the United States. Hepatology. 2018;68(3):872–82 These data from a commercial claim database highlight the rising incidence of cirrhosis and the disproportionate economic burden associated with alcohol-related liver disease.CrossRefGoogle Scholar
  8. 8.
    Scaglione S, Kliethermes S, Cao G, et al. The epidemiology of cirrhosis in the United States: a population-based study. J Clin Gastroenterol. 2015;49(8):690–6.CrossRefGoogle Scholar
  9. 9.
    Beste LA, Leipertz SL, Green PK, Dominitz JA, Ross D, Ioannou GN. Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001–2013. Gastroenterology. 2015;149(6):1471–1482.e5.CrossRefGoogle Scholar
  10. 10.••
    Flemming JA, Dewit Y, Mah JM, Saperia J, Groome PA, Booth CM. Incidence of cirrhosis in young birth cohorts in Canada from 1997 to 2016: a retrospective population-based study. Lancet Gastroenterol Hepatol. 2018. This population-based study from Ontario demonstrates a rising incidence for cirrhosis, particularly among young people.Google Scholar
  11. 11.••
    Tapper EB, Parikh ND. Mortality due to cirrhosis and liver cancer in the United States, 1999–2016: observational study. BMJ. 2018;362. This study evaluates trends in mortality due to liver disease in the USA and demonstrates substantial increases following 2008, particularly among young persons aged 25-34.Google Scholar
  12. 12.
    • Peery AF, Crockett SD, Murphy CC, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology. 2019;156(1):254–272.e11 This annual survey updates the outcomes of and healthcare costs associated with multiple gastrointerstinal illnesses.CrossRefGoogle Scholar
  13. 13.••
    Asrani SK, Hall L, Hagan M, et al. Trends in chronic liver disease-related hospitalizations: a population-based study. Am J Gastroenterol. 2018. This population-based study from Texas demonstrates that persons with chronic liver disease are at higher risk of hospitalization compared with other organ failure states such as COPD and CHF.Google Scholar
  14. 14.
    Asrani SK, Kouznetsova M, Ogola G, et al. Increasing health care burden of chronic liver disease compared with other chronic diseases, 2004–2013. Gastroenterology. 2018;155(3):719–729.e4.CrossRefGoogle Scholar
  15. 15.
    Tapper EB, Halbert B, Mellinger J. Rates of and reasons for hospital readmissions in patients with cirrhosis: a multistate population-based cohort study. Clin Gastroenterol Hepatol. 2016;14:1181–1188.e2.CrossRefGoogle Scholar
  16. 16.
    Tapper EB. Building effective quality improvement programs for liver disease: a systematic review of quality improvement initiatives. Clin Gastroenterol Hepatol. 2016;14(9):1256–1265.e3.CrossRefGoogle Scholar
  17. 17.
    Nguyen NH, Khera R, Ohno-Machado L, Sandborn WJ, Singh S. Annual burden and costs of hospitalization for high-need, high-cost patients with chronic gastrointestinal and liver diseases. Clin Gastroenterol Hepatol. 2018;16(8):1284–1292.e30.CrossRefGoogle Scholar
  18. 18.
    Tapper EB, Parikh ND, Sengupta N, et al. A risk score to predict the development of hepatic encephalopathy in a population-based cohort of patients with cirrhosis. Hepatology. 2018;68(4):1498–507.CrossRefGoogle Scholar
  19. 19.
    Patidar KR, Thacker LR, Wade JB, Sterling RK, Sanyal AJ, Siddiqui MS, et al. Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization. Am J Gastroenterol. 2014;109:1757–63.CrossRefGoogle Scholar
  20. 20.
    Bajaj JS, O’Leary JG, Tandon P, et al. Hepatic encephalopathy is associated with mortality in patients with cirrhosis independent of other extrahepatic organ failures. Clin Gastroenterol Hepatol. 2017;15(4):565–574.e4.CrossRefGoogle Scholar
  21. 21.
    Onishi Y, Wakita T, Fukuhara S, Noguchi Y, Okada M, Sakaida I, et al. Development and validation of a symptom scale specific for ascites accompanied with cirrhosis: the ASI-7. Clin Transl Gastroenterol. 2014;5(2):e48.CrossRefGoogle Scholar
  22. 22.
    Solà E, Watson H, Graupera I, Turón F, Barreto R, Rodríguez E, et al. Factors related to quality of life in patients with cirrhosis and ascites: relevance of serum sodium concentration and leg edema. J Hepatol. 2012;57(6):1199–206.CrossRefGoogle Scholar
  23. 23.
    Soriano G, Román E, Córdoba J, Torrens M, Poca M, Torras X, et al. Cognitive dysfunction in cirrhosis is associated with falls: a prospective study. Hepatology. 2012;55(6):1922–30.CrossRefGoogle Scholar
  24. 24.
    Ezaz G, Murphy SL, Mellinger J, Tapper EB. Increased morbidity and mortality associated with falls among patients with cirrhosis. Am J Med. 2018;131(6):645–650.e2.CrossRefGoogle Scholar
  25. 25.
    Oeda S, Takahashi H, Yoshida H, et al. Prevalence of pruritus in patients with chronic liver disease: a multicenter study. Hepatol Res. 2018;48(3):E252–62.CrossRefGoogle Scholar
  26. 26.
    Paternostro R, Heinisch BB, Reiberger T, et al. Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension. Liver Int. 2018;38(8):1427–36.CrossRefGoogle Scholar
  27. 27.
    Sorrell JH, Brown JR. Sexual functioning in patients with end-stage liver disease before and after transplantation. Liver Transpl. 2006;12(10):1473–7.CrossRefGoogle Scholar
  28. 28.
    Chatrath H, Liangpunsakul S, Ghabril M, Otte J, Chalasani N, Vuppalanchi R. Prevalence and morbidity associated with muscle cramps in patients with cirrhosis. Am J Med. 2012;125(10):1019–25.CrossRefGoogle Scholar
  29. 29.
    Kim BH, Choi HY, Ki M, Kim K-A, Jang ES, Jeong S-H. Population-based prevalence, incidence, and disease burden of autoimmune hepatitis in South Korea. PLoS One. 2017;12(8):e0182391.CrossRefGoogle Scholar
  30. 30.
    Lu M, Zhou Y, Haller IV, et al. Increasing prevalence of primary biliary cholangitis and reduced mortality with treatment. Clin Gastroenterol Hepatol. 2018;16(8):1342–1350. e1.CrossRefGoogle Scholar
  31. 31.
    Liang H, Manne S, Shick J, Lissoos T, Dolin P. Incidence, prevalence, and natural history of primary sclerosing cholangitis in the United Kingdom. Medicine. 2017;96(24).Google Scholar
  32. 32.
    Åsberg A, Hveem K, Thorstensen K, et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons. Scand J Gastroenterol. 2001;36(10):1108–15.CrossRefGoogle Scholar
  33. 33.
    Moon AM, Green PK, Berry K, Ioannou GN. Transformation of hepatitis C antiviral treatment in a national healthcare system following the introduction of direct antiviral agents. Aliment Pharmacol Ther. 2017;45(9):1201–12.CrossRefGoogle Scholar
  34. 34.
    van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis c and advanced hepatic fibrosis. JAMA. 2012;308(24):2584–93.CrossRefGoogle Scholar
  35. 35.
    Cholankeril G, Ahmed A. Alcoholic liver disease replaces hepatitis C virus infection as the leading indication for liver transplantation in the United States. Clin Gastroenterol Hepatol. 2018;16(8):1356–8.CrossRefGoogle Scholar
  36. 36.
    Zibbell JE, Asher AK, Patel RC, Kupronis B, Iqbal K, Ward JW, et al. Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014. Am J Public Health. 2018;108(2):175–81.CrossRefGoogle Scholar
  37. 37.
    Des Jarlais DC, Arasteh K, Feelemyer J, McKnight C, Barnes DM, Perlman DC, et al. Hepatitis C virus prevalence and estimated incidence among new injectors during the opioid epidemic in New York City, 2000–2017: protective effects of non-injecting drug use. Drug Alcohol Depend. 2018;192:74–9.CrossRefGoogle Scholar
  38. 38.
    Kim H-s, Yang JD, El-Serag HB, Kanwal F. Awareness of chronic viral hepatitis in the United States: an update from National Health and Nutrition Examination Survey. J Viral Hepat. 201Google Scholar
  39. 39.•
    Parikh ND, Marrero WJ, Wang J, et al. Projected increase in obesity and non-alcoholic-steatohepatitis–related liver transplantation waitlist additions in the United States. Hepatology. 2017. This modeling study combines multiple data sources to demonstrate how rising rates of obesity are driving an increasing burden of NAFLD and NAFLD-related cirrhosis and liver failure.Google Scholar
  40. 40.
    Parikh ND, Marrero WJ, Wang J, et al. Projected increase in obesity and non-alcoholic-steatohepatitis–related liver transplantation waitlist additions in the United States. Hepatology. 0(0).Google Scholar
  41. 41.
    Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123–33.CrossRefGoogle Scholar
  42. 42.
    •• Allen AM, Therneau TM, Larson JJ, Coward A, Somers VK, Kamath PS. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: a 20 year-community study. Hepatology. 2018;67(5):1726–36 This population-based study from Olmstead county demonstrates a rising incidene of NAFLD including among young persons.CrossRefGoogle Scholar
  43. 43.
    Ezaz G, Tapper EB. Driving in the dark: cirrhosis in young adults. Lancet Gastroenterol Hepatol. 2018.Google Scholar
  44. 44.
    Yang JC, Roman-Urrestarazu A, Brayne C. Binge alcohol and substance use across birth cohorts and the global financial crisis in the United States. PLoS One. 2018;13(6):e0199741.CrossRefGoogle Scholar
  45. 45.
    Jepsen P, Ott P, Andersen PK, Sørensen HT, Vilstrup H. Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology. 2010;51(5):1675–82.CrossRefGoogle Scholar
  46. 46.
    Nilsson E, Anderson H, Sargenti K, Lindgren S, Prytz H. Incidence, clinical presentation and mortality of liver cirrhosis in Southern Sweden: a 10-year population-based study. Aliment Pharmacol Ther. 2016;43(12):1330–9.CrossRefGoogle Scholar
  47. 47.
    Jepsen P, Lash TL, Vilstrup H. The clinical course of alcoholic cirrhosis: development of comorbid diseases. A Danish nationwide cohort study. Liver Int. 2016;36(11):1696–703.CrossRefGoogle Scholar
  48. 48.
    Asrani SK, Larson JJ, Yawn B, Therneau TM, Kim WR. Underestimation of liver-related mortality in the United States. Gastroenterology. 2013;145(2):375–382.e2.CrossRefGoogle Scholar
  49. 49.
    van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584–93.CrossRefGoogle Scholar
  50. 50.
    Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147(10):677–84.CrossRefGoogle Scholar
  51. 51.
    Teli MR, Day CP, James O, Burt A, Bennett M. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet. 1995;346(8981):987–90.CrossRefGoogle Scholar
  52. 52.
    Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130(3):678–86.CrossRefGoogle Scholar
  53. 53.
    Wiley TE, McCarthy M, Breidi L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology. 1998;28(3):805–9.CrossRefGoogle Scholar
  54. 54.
    Poupon RE, Poupon R, Balkau B. Group U-Ps. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med. 1994;330(19):1342–7.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Division of Gastroenterology and HepatologyUniversity of MichiganAnn ArborUSA
  2. 2.Gastroenterology SectionVA Ann Arbor Healthcare SystemAnn ArborUSA

Personalised recommendations